Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monopar TherapeuticsMNPR · Entity 5152 | Chief Financial Officer | October 28, 2024 | October 30, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monopar Therapeutics
Report date October 28, 2024 · Filed October 30, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,550 |
Reported balance
After 2024-10-28 transaction · row 1
1 source rowRow 1 · 2024-10-28 · Purchase · Acquired 1,550 · Balance 1,550 F1: The price reported in Column 4 is the Public offering price in the prospectus dated October 28, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is the Public offering price in the prospectus dated October 28, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2024 Filed Oct 30, 2024 16:17 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon Stock | 1,550 | $16.25 | $25,187.50 |
DisclosureSEC source: 0001437749-24-032626 · rdgdoc.xml · nonDerivative · entry 1 Radhakrishnan Karthik · CIK 0001573327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550 F1 · price: The price reported in Column 4 is the Public offering price in the prospectus dated October 28, 2024. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 18:22 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 125,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001437749-24-022213 · rdgdoc.xml · derivative · entry 1 Radhakrishnan Karthik · CIK 0001573327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Commom Stock · 125,000 shares Expires 2034-06-30 F1 · derivative.exercise_date: On July 1, 2024, the reporting person was granted 125,000 stock options, vesting 6/48ths (15,625 shares) on December 31, 2024, and 1/48th every month thereafter until the stock option is fully vested on July 1, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.